ATE439134T1 - Medikament zum schutz in der radiotherapie - Google Patents

Medikament zum schutz in der radiotherapie

Info

Publication number
ATE439134T1
ATE439134T1 AT02717355T AT02717355T ATE439134T1 AT E439134 T1 ATE439134 T1 AT E439134T1 AT 02717355 T AT02717355 T AT 02717355T AT 02717355 T AT02717355 T AT 02717355T AT E439134 T1 ATE439134 T1 AT E439134T1
Authority
AT
Austria
Prior art keywords
radiotherapy
medicine
protection
relates
protectant
Prior art date
Application number
AT02717355T
Other languages
English (en)
Inventor
J D Crapo
Brian Day
Ines Batinic-Haberle
Richard Gammans
Zeljko Vujaskovic
Original Assignee
Nat Jewish Med & Res Center
Aeolus Sciences Inc
Univ Duke
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nat Jewish Med & Res Center, Aeolus Sciences Inc, Univ Duke filed Critical Nat Jewish Med & Res Center
Application granted granted Critical
Publication of ATE439134T1 publication Critical patent/ATE439134T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/409—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having four such rings, e.g. porphine derivatives, bilirubin, biliverdine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pyrrole Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
AT02717355T 2001-01-19 2002-01-22 Medikament zum schutz in der radiotherapie ATE439134T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US26239001P 2001-01-19 2001-01-19
PCT/US2002/001507 WO2002060383A2 (en) 2001-01-19 2002-01-22 Cancer therapy

Publications (1)

Publication Number Publication Date
ATE439134T1 true ATE439134T1 (de) 2009-08-15

Family

ID=22997293

Family Applications (1)

Application Number Title Priority Date Filing Date
AT02717355T ATE439134T1 (de) 2001-01-19 2002-01-22 Medikament zum schutz in der radiotherapie

Country Status (10)

Country Link
US (2) US20030050297A1 (de)
EP (1) EP1392328B1 (de)
JP (3) JP2004520380A (de)
AT (1) ATE439134T1 (de)
AU (1) AU2002248366B2 (de)
CA (1) CA2436245C (de)
DE (1) DE60233317D1 (de)
DK (1) DK1392328T3 (de)
ES (1) ES2330728T3 (de)
WO (1) WO2002060383A2 (de)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1155019B1 (de) 1999-01-25 2005-12-07 National Jewish Medical and Research Center Substituierte porphyrine und deren therapeutische verwendungen
JP2005508864A (ja) 2001-06-01 2005-04-07 ナショナル・ジュウィッシュ・メディカル・アンド・リサーチ・センター 糖尿病の治療、または移植術における使用、または免疫寛容の誘導のためのオキシダントスカベンジャー
GB2397067B (en) * 2002-12-23 2005-05-11 Destiny Pharma Ltd Porphin & azaporphin derivatives with at least one cationic-nitrogen-containing meso-substituent for use in photodynamic therapy & in vitro sterilisation
FR2863892B1 (fr) * 2003-12-18 2007-05-11 Univ Paris Descartes Utilisation de mimetiques de la superoxyde dismutase et de la glutathion reductase comme anti-cancereux
US7807825B2 (en) 2004-02-09 2010-10-05 Duke University Substituted porphyrins
WO2005084665A1 (ja) * 2004-03-04 2005-09-15 Makoto Yuasa 金属ポルフィリン錯体包埋ニオソーム、その製造法およびこれを利用する医薬
GB2415372A (en) 2004-06-23 2005-12-28 Destiny Pharma Ltd Non photodynamical or sonodynamical antimicrobial use of porphyrins and azaporphyrins containing at least one cationic-nitrogen-containing substituent
CA2665984C (en) 2006-10-12 2017-02-28 Activbiotics, Inc. Superoxide dismutase mimetics for the treatment of oral mucositis
US8987245B2 (en) 2008-04-02 2015-03-24 Jonathan R. Brestoff Parker Composition and method for affecting obesity and related conditions
US8598150B1 (en) 2008-04-02 2013-12-03 Jonathan R. Brestoff Composition and method for affecting obesity and related conditions
US11382895B2 (en) * 2008-05-23 2022-07-12 National Jewish Health Methods for treating injury associated with exposure to an alkylating species
CA2740773A1 (en) 2008-10-14 2010-04-22 Edison Pharmaceuticals, Inc. Treatment of oxidative stress disorders including contrast nephropathy, radiation damage and disruptions in the function of red cells
ES2355784B1 (es) 2009-09-21 2012-02-03 Universitat De Valencia Complejos metalicos mimeticos de sod
CA2849456C (en) 2011-09-26 2021-12-07 Galera Therapeutics, Llc Methods for treatment of diseases
CN104080453A (zh) 2011-12-02 2014-10-01 科罗拉多大学董事会,法人团体 金属卟啉神经治疗
CN102617581B (zh) * 2012-03-15 2013-11-06 中国药科大学 58Fe氯高铁血红素、其制备及其在药动学研究中的应用
JP6154231B2 (ja) * 2013-07-22 2017-06-28 学校法人同志社 抗癌剤
HUE049926T2 (hu) 2015-08-11 2020-11-30 Galera Labs Llc Makrociklusos pentaazagyûrûkomplexek orális biológiai hozzáférhetõséggel
CN109414454A (zh) 2016-05-03 2019-03-01 加莱拉实验室有限责任公司 用于癌症治疗的组合疗法
EP3506907B1 (de) 2016-09-01 2023-06-07 Galera Labs, LLC Kombinierte krebstherapie mit einem pentaaza-makrocyclischen ring-komplex und einer ascorbatverbindung
KR20240116576A (ko) * 2017-04-04 2024-07-29 바이오미매틱스 제이브이, 엘엘씨 방사선 요법 및/또는 화학요법 노출과 연관된 부작용의 치료 및/또는 예방을 위한 방법, 조성물, 및 키트
CA3076008A1 (en) 2017-09-29 2019-04-04 Duke University Fluoro substituted porphyrin compounds, pharmaceutical compositions comprising the same, and methods of preparing and using the same
EA201992431A1 (ru) 2017-10-13 2020-03-13 ГАЛЕРА ЛЭБЗ, ЭлЭлСи Комбинированная иммунотерапия рака с использованием пента-аза-макроциклического кольцевого комплекса
IL276407B2 (en) * 2018-01-31 2025-01-01 Galera Labs Llc Combination cancer therapy with a pentase macrocyclic ring complex and a platinum-based anticancer agent
TWI669120B (zh) * 2018-05-17 2019-08-21 國立交通大學 鎳超氧歧化酶擬態化合物用於製備癌症治療藥物的用途
US12201649B2 (en) 2021-11-12 2025-01-21 Villanova University Pharmaceutical composition comprising oxidizable biphenol and manganese porphyrin, and method of using the same

Family Cites Families (88)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2951799A (en) * 1957-11-13 1960-09-06 Monsanto Chemicals Photoxidation processes using heterocyclic photosensitizers
JPS6056171B2 (ja) * 1980-03-17 1985-12-09 信越化学工業株式会社 エポキシ樹脂組成物
EP0127797B1 (de) 1983-06-03 1987-06-16 F. HOFFMANN-LA ROCHE & CO. Aktiengesellschaft Markermoleküle für Fluoreszenz-Immuno-Assays sowie Verfahren und Zwischenprodukte zu deren Herstellung
US4829984A (en) * 1983-12-15 1989-05-16 Gordon Robert T Method for the improvement of transplantation techniques and for the preservation of tissue
US4963367A (en) * 1984-04-27 1990-10-16 Medaphore, Inc. Drug delivery compositions and methods
US5087438A (en) * 1984-07-03 1992-02-11 Gordon Robert T Method for affecting intracellular and extracellular electric and magnetic dipoles
GB8429845D0 (en) * 1984-11-26 1985-01-03 Efamol Ltd Porphyrins & cancer treatment
US4758422A (en) * 1985-01-04 1988-07-19 Salutar Inc. Ferrioxamine paramagnetic contrast agents for MR imaging
US4657902A (en) * 1985-03-25 1987-04-14 The Rockefeller University Therapeutic use of tin mesoporphyrin
EP0223831B1 (de) * 1985-05-22 1992-07-15 Liposome Technology, Inc. Verfahren und system zum einatmen von liposomen
DK402785D0 (da) * 1985-09-03 1985-09-03 Syn Tek Ab Fremgangsmaade til fremstilling af et enzym
US5248603A (en) * 1985-09-03 1993-09-28 Symbicom Aktiebolag Superoxide dismutase
JPH0653670B2 (ja) * 1985-10-28 1994-07-20 日研フ−ド株式会社 化学療法剤の副作用低減化剤
US4866054A (en) * 1986-05-13 1989-09-12 Chai-Tech Corporation Antioxidant metallo-organic treatment of inflammation
US4746735A (en) * 1986-11-21 1988-05-24 The Dow Chemical Company Regiospecific aryl nitration of meso-substituted tetraarylporphyrins
US5162231A (en) * 1989-10-25 1992-11-10 Cole Dean A Method of using 5,10,15,20-tetrakis(carboxyphenyl)porphine for detecting cancers of the lung
ES2083357T3 (es) 1987-03-14 1996-04-16 Boehringer Ingelheim Int Manganeso-superoxido-dismutasa humana (hmn-sod).
US5227405A (en) * 1987-03-31 1993-07-13 Duke University Superoxide dismutase mimic
US5223538A (en) * 1987-03-31 1993-06-29 Duke University Superoxide dismutase mimic
US4892941A (en) * 1987-04-17 1990-01-09 Dolphin David H Porphyrins
US4851403A (en) * 1987-04-21 1989-07-25 Johnson Matthey, Inc. Radiation sensitizers
US4885114A (en) * 1987-04-22 1989-12-05 Barnes Engineering Co. Metallized tetra((meso)-5-methyl-2-thiophene)porphines, platinum (5-bromo octaethylporphine) and optical filters containing same
US5051337A (en) * 1987-06-10 1991-09-24 Director-General Of Agency Of Industrial Science And Technology Optical recording material
US5162519A (en) * 1988-03-11 1992-11-10 Efamol Holdings Plc Porphyrins and cancer treatment
GB8805849D0 (en) 1988-03-11 1988-04-13 Efamol Holdings Porphyrins & cancer treatment
US5284647A (en) * 1988-03-18 1994-02-08 Schering Aktiengesellschaft Mesotetraphenylporphyrin complex compounds, process for their production and pharmaceutical agents containing them
DE3809671A1 (de) 1988-03-18 1989-09-28 Schering Ag Porphyrin-komplexverbindungen, verfahren zu ihrer herstellung und diese enthaltende pharmazeutische mittel
US5109016A (en) * 1988-05-23 1992-04-28 Georgia State University Foundation, Inc. Method for inhibiting infection or replication of human immunodeficiency virus with porphyrin and phthalocyanine antiviral compositions
US5192788A (en) * 1988-05-23 1993-03-09 Georgia State University Foundation, Inc. Porphyrin antiviral compositions
FR2632187B1 (fr) 1988-06-02 1990-09-14 Centre Nat Rech Scient Derives de metalloporphyrines, leur preparation, leur application en therapeutique et leur utilisation pour la preparation de molecules hybrides
US5171680A (en) * 1988-06-14 1992-12-15 Chiron Corporation Superoxide dismutase analogs having novel binding properties
JPH0746212B2 (ja) 1988-12-03 1995-05-17 工業技術院長 異方性ｌｂ膜の製造法
EP0414915B1 (de) 1989-03-06 1996-06-12 Suntory Limited Neue superoxyd-dismutase
DK455789D0 (da) 1989-09-15 1989-09-15 Symbicom Ab Polypeptid
US5010073A (en) * 1989-10-05 1991-04-23 The Rockefeller University Use of liposomes as carriers for metalloporphyrins
EP0424033A3 (en) * 1989-10-19 1991-07-31 Pola Chemical Industries Inc External skin preparation
JPH03273082A (ja) 1990-03-20 1991-12-04 Dai Ichi Seiyaku Co Ltd 過酸化物消去剤
US5236915A (en) * 1990-05-31 1993-08-17 Health Research, Inc. Meso poly(4-sulfonatophenyl) porphines as MRI image enhancing agents
EP0462836A3 (en) 1990-06-20 1992-08-26 Mitsui Toatsu Chemicals, Inc. Recombinant vector plasmid capable of expressing human manganese superoxide dismutase, and process of producing this enzyme
US5202317A (en) * 1990-09-13 1993-04-13 The Regents Of The University Of California Synthetic drug molecules that mimic metalloenzymes
US5217966A (en) * 1990-09-13 1993-06-08 The Regents Of The University Of California Synthetic drug molecules that mimic metalloenzymes
WO1992008482A1 (en) * 1990-11-14 1992-05-29 Uab Research Foundation Compositions for reducing oxidative injury
US5192757A (en) * 1990-12-20 1993-03-09 Glaxo Inc. Cobalt porphyrins
FR2676738B1 (fr) 1991-05-22 1995-05-05 Ir2M Nouveau derive organique de metal de transition a structure porphyrinique, composition therapeutique le contenant, en particulier a activite hypoglycemiante.
KR0145953B1 (ko) 1991-07-19 1998-08-17 제임스 클리프튼 보올딩 슈퍼옥사이드의 불균화촉매로서 효과적인 질소를 포함하는 마크로사이클 릭리간드의 망간착물
CA2072934C (en) * 1991-07-19 2007-08-28 Karl William Aston Manganese complexes of nitrogen-containing macrocyclic ligands effective as catalysts for dismutating superoxide
US5262532A (en) * 1991-07-22 1993-11-16 E.R. Squibb & Sons, Inc. Paramagnetic metalloporphyrins as contrast agents for magnetic resonance imaging
US5212300A (en) 1991-09-12 1993-05-18 Sun Company, Inc. (R&M) Cyano- and polycyanometallo-porphyrins as catalysts for alkane oxidation
US6011146A (en) * 1991-11-15 2000-01-04 Institut Pasteur Altered major histocompatibility complex (MHC) determinant and methods of using the determinant
US5493017A (en) * 1992-08-14 1996-02-20 The Trustees Of The University Of Pennsylvania Ring-metalated porphyrins
US5599924A (en) * 1992-08-14 1997-02-04 Trustees Of The University Of Pennsylvania Electron-deficient porphyrins and processes and intermediates for preparing same
US5403834A (en) * 1992-12-07 1995-04-04 Eukarion, Inc. Synthetic catalytic free radical scavengers useful as antioxidants for prevention and therapy of disease
US5834509A (en) * 1992-12-07 1998-11-10 Eukarion, Inc. Synthetic catalytic free radical scavengers useful as antioxidants for prevention and therapy of disease
US5696109A (en) * 1992-12-07 1997-12-09 Eukarion, Inc. Synthetic catalytic free radical scavengers useful as antioxidants for prevention and therapy of disease
US6204259B1 (en) * 1993-01-14 2001-03-20 Monsanto Company Manganese complexes of nitrogen-containing macrocyclic ligands effective as catalysts for dismutating superoxide
DE4305523A1 (de) * 1993-02-17 1994-08-18 Diagnostikforschung Inst Meso-Tetraphenylporphyrin-Komplexverbindungen, Verfahren zu ihrer Herstellung und diese enthaltende pharmazeutische Mittel
US5824781A (en) * 1993-08-16 1998-10-20 Hsia; Jen-Chang Compositions and methods utilizing nitroxides in combination with biocompatible macromolecules
US6417182B1 (en) * 1993-08-25 2002-07-09 Anormed Inc. Pharmaceutical compositions comprising metal complexes
US5747026A (en) * 1993-10-15 1998-05-05 University Of Alabama At Birmingham Research Foundation Antioxidants
US6127356A (en) * 1993-10-15 2000-10-03 Duke University Oxidant scavengers
US5994339A (en) * 1993-10-15 1999-11-30 University Of Alabama At Birmingham Research Foundation Oxidant scavengers
US5608054A (en) * 1993-12-29 1997-03-04 Sun Company, Inc. (R&M) Porphyrins and metal complexes thereof having haloalkyl side chains
US5405369A (en) * 1994-01-25 1995-04-11 Medical College Of Ohio Photochemical ablation of gastro-intestinal tissue for augmentation of an organ
JP3716296B2 (ja) 1994-02-25 2005-11-16 独立行政法人放射線医学総合研究所 放射線障害防護剤
US5604199A (en) * 1994-03-29 1997-02-18 The Nemours Foundation Method of treating fibrosis in skeletal muscle tissue
US6245758B1 (en) * 1994-05-13 2001-06-12 Michael K. Stern Methods of use for peroxynitrite decomposition catalysts, pharmaceutical compositions therefor
PL317192A1 (en) * 1994-05-13 1997-03-17 Monsanto Co Methods of using pernitrite decomposition catalyst and their pharmaceutic compositions
US5563132A (en) * 1994-06-21 1996-10-08 Bodaness; Richard S. Two-step cancer treatment method
WO1996009053A1 (en) * 1994-09-20 1996-03-28 Duke University Oxidoreductase activity of manganic porphyrins
US6013241A (en) * 1995-01-23 2000-01-11 Schering Aktiengesellschaft Use of porphyrin-complex or expanded porphyrin-complex compounds as an infarction localization diagnosticum
US5976498A (en) * 1995-08-17 1999-11-02 Neumann; William L. Methods of diagnostic image analysis using metal complexes of nitrogen-containing macrocyclic ligands
US5648523A (en) * 1995-10-26 1997-07-15 Chiang Long Y Fullerene derivatives as free-radical scavengers
JPH09176187A (ja) 1995-12-27 1997-07-08 Kagaku Gijutsucho Hoshasen Igaku Sogo Kenkyusho 活性酸素消去能を有するヒスチジン含有ペプチド
US5948771A (en) * 1996-01-31 1999-09-07 The Trustees Of Columbia University In The City Of New York Method for treating heart failure using tetrapyrroles and metallotetrapyrroles
US5756492A (en) * 1996-09-09 1998-05-26 Sangstat Medical Corporation Graft survival prolongation with porphyrins
CA2283057A1 (en) 1997-02-05 1998-08-06 Board Of Regents, The University Of Texas System Porphyrin compounds as telomerase inhibitors
US6214817B1 (en) * 1997-06-20 2001-04-10 Monsanto Company Substituted pyridino pentaazamacrocyle complexes having superoxide dismutase activity
US6180620B1 (en) * 1997-06-20 2001-01-30 G.D. Searle & Co. Analgesic methods using synthetic catalysts for the dismutation of superoxide radicals
JP2001521939A (ja) * 1997-11-03 2001-11-13 デューク・ユニバーシティー 置換されたポルフィリン類
JP3101875B2 (ja) 1998-12-04 2000-10-23 末綱 陽子 新規なトリペプチドおよび活性化酸素阻害剤
EP1155019B1 (de) * 1999-01-25 2005-12-07 National Jewish Medical and Research Center Substituierte porphyrine und deren therapeutische verwendungen
US6608050B2 (en) * 1999-07-20 2003-08-19 Pharmacia & Upjohn Company Lyophilizate of lipid complex of water insoluble porphyrins
AU1087401A (en) * 1999-10-13 2001-04-23 Uab Research Foundation Metalloporphyrin treatment of neurologic disease
AU771600B2 (en) * 1999-11-30 2004-03-25 Photochemical Co., Ltd. Nitroimidazole-supporting porphyrin complex
JP3383839B2 (ja) * 2000-03-13 2003-03-10 奈良先端科学技術大学院大学長 新規なメルカプト置換イミダゾリルポルフィリン金属錯体単量体及びこれを繰り返し単位として有する重合体並びにこれらの製造方法
US6624187B1 (en) * 2000-06-12 2003-09-23 Health Research, Inc. Long wave length absorbing bacteriochlorin alkyl ether analogs
US6403788B1 (en) * 2000-07-11 2002-06-11 Eukarion, Inc. Non-genotoxic metalloporphyrins as synthetic catalytic scavengers of reactive oxygen species
US6566517B2 (en) * 2001-06-06 2003-05-20 Brookhaven Science Associates, Llc Metalloporphyrins and their uses as imageable tumor-targeting agents for radiation therapy

Also Published As

Publication number Publication date
JP2004520380A (ja) 2004-07-08
JP2012087148A (ja) 2012-05-10
US20030050297A1 (en) 2003-03-13
DE60233317D1 (de) 2009-09-24
JP2009242421A (ja) 2009-10-22
AU2002248366B2 (en) 2006-10-26
CA2436245C (en) 2013-04-23
EP1392328A2 (de) 2004-03-03
WO2002060383A2 (en) 2002-08-08
DK1392328T3 (da) 2009-11-09
WO2002060383A3 (en) 2003-12-11
CA2436245A1 (en) 2002-08-08
EP1392328B1 (de) 2009-08-12
EP1392328A4 (de) 2004-11-17
US8765729B2 (en) 2014-07-01
ES2330728T3 (es) 2009-12-15
US20070149498A1 (en) 2007-06-28

Similar Documents

Publication Publication Date Title
DE60233317D1 (de) Medikament zum schutz in der radiotherapie
MX2007002398A (es) Nuevas composiciones farmaceuticas para el tratamiento de cancer.
MXPA06000933A (es) Compuestos de aminopirazol y uso como inhibidores de chk1.
BR0308854A (pt) Benzazolas substituìdas e seus usos como inibidoras de quinase raf
MY191349A (en) New pharmaceutical compositions for the treatment of hyper-proliferative disorders
AU747599C (en) Antitumor agents
WO2006020722A3 (en) Polymer conjugates of beta-lapachone and beta-lapachone analogs for tumor targeting
JO2373B1 (en) W-carboxy-aryl diphenyl urease substitutes used as RAV inhibitors
SG164368A1 (en) Treatment of cancer
TNSN07341A1 (en) Pharmaceutical composition comprising an omega-carboxyaryl substituted diphenyl urea for the treatment of cancer
WO2004093831A3 (en) Cytokine-expressing cellular vaccine combinations
NO20032759L (no) 2-fenylbenzimidazoler og imidazo-[4,5]-pyridiner som Cds1/Chk2-inhibitorerog adjuvanter for kjemoterapi eller strålingsterapi ved behandlingav cancer
PL308217A1 (en) Derivatives of 1-(oxo-acetyl)-piperidine-2-carboxylic as agents sensibilising multiple-drug-resistant cancer cells
TNSN07193A1 (en) Pharmaceutical compositions comprising a camptothecin derivate
NO20071428L (no) Kombinasjon inneholdende ZD6474 og Imatinib
MXPA05011076A (es) Derivados de quinazolina para el tratamiento de cancer.
BRPI0318278B8 (pt) Compostos de éter aminocicloexílico, composição compreendendo ditos compostos, usos dos mesmos e método para modular a atividade do canal iônico em um ambiente in vitro
WO2005016264A3 (en) Diamine derivatives of quinone and uses thereof
MX2007014920A (es) Politerapia que comprende diarilureas para el tratamiento de enfermedades.
TW200505452A (en) Chemical compounds
YU64602A (sh) Smeša koja se sastoji od kamptotecina i derivata pirimidina za terapiju kancera
EP1478660A4 (de) Kappa-pviia-verwandte conotoxine als mittel zum schutz von organen
NO20064753L (no) Kombinasjonsterapi
DE60221104D1 (de) Substituierte diarylharnstoffe als stimulatoren der fas-vermittelten apoptose
TR200200987T2 (tr) Kanser tedavisine yönelik,ornatılmış pirroller

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties